Latest news
A study performed in the molecular biology and genetics laboratory at Instituto Bernabeu, IB Biotech, and submitted to the Spanish Fertility Society (SEF) congress has concluded that there is an increased risk of embryo abnormalities in chromosomal segments in young women.
Research carried out by Instituto Bernabeu has concluded that the use of heparin, an anticoagulant drug, improves prognosis in courses of in vitro fertilisation treatment (IVF) and ICSI (intracytoplasmic sperm injection) in patients who have experienced recurrent pregnancy loss or repeated implantation failure.
Instituto Bernabeu has submitted research work managed by Belén Lledó, Director of the clinic's Genetics Unit, to the Spanish Fertility Society (SEF) congress. The research involved analysis of mitochondrial DNA (mtDNA) in embryos and its link to the success of in vitro fertilisation treatment (IVF).
Instituto Bernabeu has submitted research work to the 32nd Spanish Fertility Society (SEF) National Congress held in Madrid. The aim of the study is to gain an understanding of drugs under conditions that differ from authorised use for courses of in vitro fertilisation (IVF) in patients with poor response, the frequency with which they are used in these cases and a review of the legal side to their administration. The research work is entitled: ‘Use of drugs under different conditions to those authorised within the framework of a course of in vitro fertilisation: a review of legal aspects and experience of use in patients with poor ovarian response.’